Canadian Body Calls For Investment In Domestic Production

CGPA Blueprint Also Urges Enhanced International Role And Local Stockpiling

In a new “blueprint” document, the CGPA has called for investment in Canada’s domestic generic pharmaceutical infrastructure to bolster its manufacturing and supply capabilities, as well as urging an enhanced international role and a local stockpile of essential drugs.

Barcode_Canada
The CGPA has urged renewed investment in domestic manufacturing • Source: Shutterstock

Investment in Canada’s domestic pharmaceutical infrastructure is essential to ensure that the country has a “secure and consistent supply of prescription medicines,” the Canadian Generic Pharmaceutical Association has urged. The call comes as part of a “blueprint” document published by the body that also insists that an enhanced international role is needed for Canada, as well as engagement with manufacturers to create a local stockpile of essential drugs.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Manufacturing

More from Business